Barbara Ensoli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2655887/publications.pdf

Version: 2024-02-01

230 papers	14,559 citations	20817 60 h-index	22832 112 g-index

232 all docs	232 docs citations	232 times ranked	8746 citing authors

#	Article	IF	Citations
1	Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature, 1990, 345, 84-86.	27.8	921
2	Global trends in molecular epidemiology of HIV-1 during 2000â€“2007. Aids, 2011, 25, 679-689.	2.2	602
3	Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature, 1994, 371, 674-680.	27.8	592
4	AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science, 1989, 243, 223-226.	12.6	464
5	HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. Aids, 1997, 11, 1421-1431.	2.2	412
6	The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science, 1987, 237, 888-893.	12.6	408
7	Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature, 1989, 337, 370-373.	27.8	354
8	Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science, 1988, 242, 426-430.	12.6	353
9	The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7941-7945.	7.1	333
10	Biologically diverse molecular variants within a single HIV-1 isolate. Nature, 1988, 334, 444-447.	27.8	309
11	HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Medicine, 2002, 8, 225-232.	30.7	299
12	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nature Medicine, 1999, 5, 643-650.	30.7	288
13	Global and regional molecular epidemiology of HIV-1, 1990â€“2015: a systematic review, global survey, and trend analysis. Lancet Infectious Diseases, The, 2019, 19, 143-155.	9.1	255
14	Biology of Kaposi's sarcoma. European Journal of Cancer, 2001, 37, 1251-1269.	2.8	228
15	Angiogenic properties of human immunodeficiency virus type 1 Tat protein.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4838-4842.	7.1	209
16	Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science, 1990, 247, 848-852.	12.6	175
17	Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine and Growth Factor Reviews, 1998, 9, 63-83.	7.2	173
18	The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO Journal, 2001, 20, 5568-5577.	7.8	166

#	Article	IF	Citations
19	Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses. Journal of Immunology, 2002, 168, 197-206.	0.8	158
20	Expression of K13/v-FLIP Gene of Human Herpesvirus 8 and Apoptosis in Kaposi's Sarcoma Spindle Cells. Journal of the National Cancer Institute, 1999, 91, 1725-1733.	6.3	156
21	Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.. Journal of Clinical Investigation, 1995, 95, 1723-1734.	8.2	150
22	Cytokines and Growth Factors in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. Immunological Reviews, 1992, 127, 147-155.	6.0	148
23	High Seroprevalence of Antibodies to Human Herpesvirus-8 in Egyptian Children: Evidence of Nonsexual Transmission. Journal of the National Cancer Institute, 1999, 91, 465-469.	6.3	139
24	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine, 2001, 19, 2862-2877.	3.8	135
25	Human Herpesvirus 8 Seropositivity and Risk of Kaposi's Sarcoma and Other Acquired Immunodeficiency Syndrome-Related Diseases. Journal of the National Cancer Institute, 1999, 91, 1468-1474.	6.3	130
26	Guanylate-Binding Protein-1 Expression Is Selectively Induced by Inflammatory Cytokines and Is an Activation Marker of Endothelial Cells during Inflammatory Diseases. American Journal of Pathology, 2002, 161, 1749-1759.	3.8	129
27	Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines. Journal of Immunology, 2009, 182, 3718-3727.	0.8	128
28	Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncology, The, 2003, 4, 537-547.	10.7	125
29	Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.. Journal of Clinical Investigation, 1994, 94, 1736-1746.	8.2	125
30	The Presence of Antiâ€Tat Antibodies Is Predictive of Longâ€Term Nonprogression to AIDS or Severe Immunodeficiency: Findings in a Cohort of HIVâ€1 Seroconverters. Journal of Infectious Diseases, 2005, 191, 1321-1324.	4.0	118
31	Angiogenic Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein and Its Role in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. Clinical Microbiology Reviews, 2002, 15, 310-326.	13.6	115
32	The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. European Journal of Immunology, 2002, 32, 2857-2865.	2.9	113
33	Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability In Vivo by Human Immunodeficiency Virus-1 Tat Protein and Basic Fibroblast Growth Factor. Molecular Biology of the Cell, 2001, 12, 2934-2946.	2.1	110
34	Variability and evolution of Kaposiâ€šs sarcoma-associated herpesvirus in Europe and Africa. Aids, 1999, 13, 1165-1176.	2.2	107
35	Î³-Interferon Production in Peripheral Blood Mononuclear Cells and Tumor Infiltrating Lymphocytes From Kaposi's Sarcoma Patients: Correlation With the Presence of Human Herpesvirus-8 in Peripheral Blood Mononuclear Cells and Lesional Macrophages. Blood, 1998, 91, 968-976.	1.4	104
36	Modulation of Human Immunodeficiency Virus 1 Replication by Interferon Regulatory Factors. Journal of Experimental Medicine, 2002, 195, 1359-1370.	8.5	102

#	Article	IF	Citations
37	New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature, 1987, 328, 548-550.	27.8	101
38	HIV-1 Tat Protein Modulates the Generation of Cytotoxic T Cell Epitopes by Modifying Proteasome Composition and Enzymatic Activity. Journal of Immunology, 2004, 173, 3838-3843.	0.8	101
39	Prevalence, Incidence and Correlates of HHV-8/KSHV Infection and Kaposi's Sarcoma in Renal and Liver Transplant Recipients. Journal of Infection, 2001, 43, 195-199.	3.3	97
40	Antitumour effects of antiretroviral therapy. Nature Reviews Cancer, 2004, 4, 861-875.	28.4	95
41	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. PLoS ONE, 2010, 5, e13540.	2.5	94
42	Pathogenesis of AIDS-Associated Kaposi's Sarcoma. Hematology/Oncology Clinics of North America, 1991, 5, 281-295.	2.2	91
43	Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. , 1998, 77, 361-365.		89
44	NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. European Journal of Immunology, 2002, 32, 2711-2720.	2.9	84
45	IRF-1 Is Required for Full NF-ÎºB Transcriptional Activity at the Human Immunodeficiency Virus Type 1 Long Terminal Repeat Enhancer. Journal of Virology, 2008, 82, 3632-3641.	3.4	83
46	Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 tat protein. Journal of Biomedical Science, 1995, 2, 189-202.	7.0	82
47	A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV 89.6P Challenge in Rhesus Macaques. Journal of Virology, 2007, 81, 3414-3427.	3.4	80
48	Mechanism of Paclitaxel Activity in Kaposiâ€™s Sarcoma. Journal of Immunology, 2000, 165, 509-517.	0.8	75
49	Sequence Conservation and Antibody Crossâ€Recognition of Clade B Human Immunodeficiency Virus (HIV) Type 1 Tat Protein in HIVâ€1â€“Infected Italians, Ugandans, and South Africans. Journal of Infectious Diseases, 2003, 188, 1171-1180.	4.0	75
50	Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Advances in Cancer Research, 2001, 81, 161-200.	5.0	72
51	Approaches to preventative and therapeutic HIV vaccines. Current Opinion in Virology, 2016, 17, 104-109.	5.4	72
52	Cytokine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma. Seminars in Cancer Biology, 2000, 10, 367-381.	9.6	71
53	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine, 2004, 22, 3258-3269.	3.8	70
54	Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells. Journal of Virology, 1999, 73, 4029-4041.	3.4	70

#	Article	IF	Citations
55	Human herpesvirus-8 and Kaposi's sarcoma: Relationship with the multistep concept of tumorigenesis. Advances in Cancer Research, 2001, 81, 125-159.	5.0	69
56	Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing Î±5Î²1 integrin expression and function. Atherosclerosis, 2001, 154, 377-385.	0.8	68
57	HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway. Molecular Biology of the Cell, 2006, 17, 1985-1994.	2.1	66
58	HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection. Journal of Immunology, 2009, 182, 2888-2897.	0.8	65
59	Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. European Journal of Immunology, 2003, 33, 1548-1556.	2.9	64
60	Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of KaposiÊ¼s sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter. Aids, 1998, 12, 19-27.	2.2	63
61	Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. Aids, 2006, 20, 2245-2261.	2.2	61
62	Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors inMacaca fascicularis NK cells. European Journal of Immunology, 2001, 31, 3546-3556.	2.9	60
63	Interactions between endothelial cells and HIV-1. International Journal of Biochemistry and Cell Biology, 2001, 33, 371-390.	2.8	59
64	Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine, 2009, 27, 3306-3312.	3.8	59
65	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. Journal of Medical Virology, 2001, 65, 123-132.	5.0	56
66	The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine, 2009, 28, 371-378.	3.8	56
67	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. PLoS ONE, 2012, 7, e48781.	2.5	56
68	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology, 2015, 12, 33.	2.0	55
69	Challenges in HIV Vaccine Research for Treatment and Prevention. Frontiers in Immunology, 2014, 5, 417.	4.8	52
70	Prevalence and Risk Factors for Human Herpesvirus 8 Infection in Northern Cameroon. Sexually Transmitted Diseases, 2000, 27, 159-164.	1.7	51
71	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. Journal of Medical Primatology, 2003, 29, 193-208.	0.6	51
72	The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. Aids, 2008, 22, 2207-2209.	2.2	51

#	Article	IF	Citations
73	Global and regional epidemiology of HIV-1 recombinants in 1990â€“2015: a systematic review and global survey. Lancet HIV,the, 2020, 7, e772-e781.	4.7	51
74	Circulating spindle cells: correlation with human herpesvirus-8 (HHV-8) infection and Kaposi's sarcoma. Lancet, The, 1997, 349, 255.	13.7	50
75	Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine, 2006, 24, 2049-2056.	3.8	50
76	Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochemical Journal, 2006, 396, 371-380.	3.7	50
77	Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. Journal of Virology, 2004, 78, 3333-3342.	3.4	49
78	The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine, 2008, 26, 727-737.	3.8	49
79	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology, 2014, 11, 49.	2.0	48
80	Limited expression of R5-tropic HIV-1 in CCR5-positive type 1â€“polarized T cells explained by their ability to produce RANTES, MIP-1Î±, and MIP-1Î². Blood, 2000, 95, 1167-1174.	1.4	47
81	A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. European Journal of Epidemiology, 2001, 17, 871-876.	5.7	47
82	DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine, 2006, 24, 5655-5669.	3.8	46
83	Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids. Journal of Clinical Microbiology, 2002, 40, 4652-4658.	3.9	45
84	Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. Immunology, 2002, 106, 395-403.	4.4	45
85	Functional Polymeric Nano/Microparticles for Surface Adsorption and Delivery of Protein and DNA Vaccines. Current Drug Delivery, 2008, 5, 230-242.	1.6	44
86	HIV-1 Infection of Primary Human Neuroblasts. Virology, 1995, 210, 221-225.	2.4	43
87	Review: IRF Regulation of HIV-1 Long Terminal Repeat Activity. Journal of Interferon and Cytokine Research, 2002, 22, 27-37.	1.2	43
88	Kaposi's Sarcoma Pathogenesis: A Link between Immunology and Tumor Biology. Critical Reviews in Oncogenesis, 1998, 9, 107-124.	0.4	43
89	Inhibition of Human Immunodeficiency Virus Type-1 by Retroviral Vectors Expressing Antisense-TAR. Human Gene Therapy, 1994, 5, 1467-1475.	2.7	41
90	Molecular and Functional Characterization of NKG2D, NKp80, and NKG2C Triggering NK Cell Receptors in Rhesus and Cynomolgus Macaques: Monitoring of NK Cell Function during Simian HIV Infection. Journal of Immunology, 2005, 174, 5695-5705.	0.8	41

#	Article	IF	Citations
91	Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. Vaccine, 2003, 21, 2073-2081.	3.8	40
92	Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection. Vaccine, 2008, 26, 3312-3321.	3.8	40
93	Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasomeâ€independent block of angiogenesis and matrix metalloproteinases. International Journal of Cancer, 2011, 128, 82-93.	5.1	40
94	Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. Journal of Medical Primatology, 2001, 30, 207-214.	0.6	39
95	Recent Advances in the Development of HIV-1 Tat-Based Vaccines. Current HIV Research, 2004, 2, 357-376.	0.5	39
96	Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine, 2004, 22, 2910-2924.	3.8	39
97	Induction of humoral and enhanced cellular immune responses by novel coreâ€“shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine, 2009, 27, 3605-3615.	3.8	39
98	HIV-1 Tat affects the programming and functionality of human CD8+ T cells by modulating the expression of T-box transcription factors. Aids, 2014, 28, 1729-1738.	2.2	39
99	HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development. International Reviews of Immunology, 2009, 28, 285-334.	3.3	38
100	Human herpesvirus-8 (HHV-8) gene expression in Kaposi's sarcoma (KS) primary lesions: an in situ hybridization study. Leukemia, 1999, 13, S110-S112.	7.2	37
101	Differential activation of the extracellular signal-regulated kinase, Jun Kinase and Janus Kinase-Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS-derived KaposiÊ¼s sarcoma cells. Aids, 1996, 10, 369-378.	2.2	35
102	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. DNA and Cell Biology, 2002, 21, 599-610.	1.9	35
103	Evaluation of a Self-Inactivating Lentiviral Vector Expressing Simian Immunodeficiency Virus Gag for Induction of Specific Immune Responsesin Vitroandin Vivo. Viral Immunology, 2006, 19, 690-701.	1.3	35
104	The HIV-1 Tat Protein Induces the Activation of CD8+ T Cells and Affects In Vivo the Magnitude and Kinetics of Antiviral Responses. PLoS ONE, 2013, 8, e77746.	2.5	35
105	Transcription Pattern of Human Herpesvirus 8 Open Reading Frame K3 in Primary Effusion Lymphoma and Kaposi's Sarcoma. Journal of Virology, 2001, 75, 7161-7174.	3.4	34
106	Isolation and characterization of lymphatic microvascular endothelial cells from human tonsils. Journal of Cellular Physiology, 2006, 207, 107-113.	4.1	34
107	Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes. Pharmaceutical Research, 2007, 24, 1870-1882.	3.5	34
108	Basic fibroblast growth factor supports human olfactory neurogenesis by autocrine/paracrine mechanisms. Neuroscience, 1998, 86, 881-893.	2.3	33

#	Article	IF	Citations
109	Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. Aids, 2012, 26, 909-919.	2.2	33
110	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology, 2016, 13, 34.	2.0	33
111	The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naÃ¯ve CD4+ T cells. Aids, 2018, 32, 575-581.	2.2	33
112	Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Current Opinion in Biotechnology, 2004, 15, 543-556.	6.6	32
113	Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opinion on Emerging Drugs, 2007, 12, 23-48.	2.4	31
114	Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. Aids, 2009, 23, 534-538.	2.2	31
115	Clinical and immunological findings in four infants with Omenn's syndrome: A form of severe combined immunodeficiency with phenotypically normal T cells, elevated IgE, and eosinophilia. Clinical Immunology and Immunopathology, 1987, 44, 123-133.	2.0	30
116	HIV-1 Gene Expression and Replication in Neuronal and Glial Cell Lines with Immature Phenotype: Effects of Nerve Growth Factor. Virology, 1994, 200, 668-676.	2.4	30
117	Impact of Viral Dose and Major Histocompatibility Complex Class IB Haplotype on Viral Outcome in Mauritian Cynomolgus Monkeys Vaccinated with Tat upon Challenge with Simian/Human Immunodeficiency Virus SHIV89.6P. Journal of Virology, 2010, 84, 8953-8958.	3.4	30
118	Human Herpesvirus-8 and Other Viral Infections, Papua New Guinea. Emerging Infectious Diseases, 2001, 7, 893-895.	4.3	29
119	Entrance of the Tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels. Oncology Letters, 2016, 12, 2389-2394.	1.8	29
120	Purified Tat induces inflammatory response genes in KaposiÊ¼s sarcoma cells. Aids, 1998, 12, 1753-1761.	2.2	28
121	Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Aids, 2000, 14, 1647-1653.	2.2	28
122	Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine, 2002, 20, 2303-2317.	3.8	28
123	Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine, 2003, 21, 3972-3981.	3.8	28
124	Human CD38 interferes with HIVâ€1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.. FASEB Journal, 2003, 17, 1-20.	0.5	28
125	HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity. Journal of Antimicrobial Chemotherapy, 2003, 51, 207-211.	3.0	28
126	Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine, 2003, 21, 1103-1111.	3.8	27

#	Article	IF	Citations
127	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice. Journal of General Virology, 2006, 87, 1625-1634.	2.9	26
128	Immobilized HIVâ€1 Tat protein promotes gene transfer via a transactivationâ€independent mechanism which requires binding of Tat to viral particles. Journal of Gene Medicine, 2009, 11, 955-965.	2.8	26
129	Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules. Vaccine, 2011, 29, 6823-6829.	3.8	26
130	Treatment of KaposiÊ¼s sarcomaâ€”an update. Anti-Cancer Drugs, 2002, 13, 977-987.	1.4	24
131	Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology, 2005, 342, 1-12.	2.4	24
132	ATL. International Journal of Gynecological Cancer, 2013, 23, 1663-1669.	2.5	24
133	Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. Aids, 2014, 28, 2189-2200.	2.2	24
134	Molecular Mechanisms in the Pathogenesis of AIDS-Associated Kaposiâ€™s Sarcoma. Advances in Experimental Medicine and Biology, 1991, 303, 27-38.	1.6	24
135	Coreâ€“shell microspheres by dispersion polymerization as promising delivery systems for proteins. Journal of Biomaterials Science, Polymer Edition, 2005, 16, 1557-1574.	3.5	23
136	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. Frontiers in Immunology, 2019, 10, 233.	4.8	23
137	Kaposi sarcoma-associated herpesvirus/human herpesvirus 8, cytokines, growth factors and HIV in pathogenesis of KaposiÊ¼s sarcoma. Current Opinion in Infectious Diseases, 1998, 11, 97-106.	3.1	22
138	Serum Concentrations of Fibroblast Growth Factor 2 Are Increased in HIV Type 1-Infected Patients and Inversely Related to Survival Probability. AIDS Research and Human Retroviruses, 2001, 17, 1035-1039.	1.1	22
139	NKp44 expression, phylogenesis and function in non-human primate NK cells. International Immunology, 2009, 21, 245-255.	4.0	22
140	HIV-1 Tat vaccines. Virus Research, 2001, 82, 91-101.	2.2	21
141	Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 Î”V2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine, 2008, 26, 1214-1227.	3.8	20
142	A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine, 2011, 29, 2918-2932.	3.8	20
143	CD4-Independent Infection of Two CD4âº/CCR5âº/CXCR4+ Pre-T-Cell Lines by Human and Simian Immunodeficiency Viruses. Journal of Virology, 2000, 74, 6689-6694.	3.4	19
144	Complex associates of plasmid DNA and a novel class of block copolymers with PEG and cationic segments as new vectors for gene delivery. Journal of Biomaterials Science, Polymer Edition, 2001, 12, 209-228.	3.5	19

#	Article	IF	Citations
145	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. Expert Opinion on Biological Therapy, 2015, 15, 13-29.	3.1	19
146	Viral outcome of simianâ€“human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Archives of Virology, 2008, 153, 463-472.	2.1	18
147	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P_{cy243}. Viral Immunology, 2009, 22, 117-124.	1.3	18
148	Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort. BMC Infectious Diseases, 2016, 16, 344.	2.9	18
149	Expression of human herpesvirus-8 (HHV-8) encoded pathogenic genes in Kaposi's Sarcoma (KS) primary lesions. Advances in Enzyme Regulation, 1999, 39, 331-339.	2.6	17
150	Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant Î”V2 Env. Microbes and Infection, 2005, 7, 1392-1399.	1.9	17
151	Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. Journal of Medical Primatology, 2007, 36, 180-194.	0.6	17
152	Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. Vaccine, 2001, 19, 3408-3419.	3.8	16
153	On the Role of Interferon Regulatory Factors in HIV-1 Replication. Annals of the New York Academy of Sciences, 2003, 1010, 29-42.	3.8	16
154	Block of Tat-Mediated Transactivation of Tumor Necrosis Factor Î² Gene Expression by Polymeric-TAR Decoys. Virology, 1996, 222, 252-256.	2.4	15
155	Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking. Molecular and Cellular Biochemistry, 2010, 345, 105-118.	3.1	15
156	The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies. International Journal of Molecular Sciences, 2018, 19, 1418.	4.1	15
157	An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge. PLoS ONE, 2014, 9, e100844.	2.5	15
158	Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. Vaccine, 2006, 24, 7148-7158.	3.8	14
159	Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine, 2016, 34, 2216-2224.	3.8	14
160	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines, 2019, 7, 99.	4.4	14
161	HIV protease inhibitors as new treatment options for Kaposiâ€™s sarcoma. Drug Resistance Updates, 2003, 6, 173-181.	14.4	13
162	Innovative Approaches to Develop Prophylactic and Therapeutic Vaccines against HIV/AIDS. Advances in Experimental Medicine and Biology, 2009, 655, 189-242.	1.6	13

#	Article	IF	Citations
163	The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. Angiogenesis, 2014, 17, 831-838.	7.2	13
164	HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells. Cell Death and Differentiation, 2004, 11, 782-784.	11.2	12
165	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. Virology, 2004, 324, 531-539.	2.4	12
166	Identification of recent HIV infections and of factors associated with virus acquisition among pregnant women in 2004 and 2006 in Swaziland. Journal of Clinical Virology, 2010, 48, 180-183.	3.1	12
167	Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: Implications for atherogenesis. Atherosclerosis, 2010, 210, 400-406.	0.8	12
168	Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. International Journal of Vascular Medicine, 2011, 2011, 1-8.	1.0	12
169	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Review of Vaccines, 2020, 19, 71-84.	4.4	12
170	HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. International Journal of Molecular Sciences, 2021, 22, 317.	4.1	12
171	Analysis of the Signal Transduction Pathway Leading to Human Immunodeficiency Virus-1-Induced Interferon Regulatory Factor-1 Upregulation. Annals of the New York Academy of Sciences, 2004, 1030, 187-195.	3.8	11
172	Criteria for selection of HIV vaccine candidatesâ€"general principles. Microbes and Infection, 2005, 7, 1433-1435.	1.9	11
173	Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. British Journal of Haematology, 2005, 130, 92-95.	2.5	11
174	Candidate HIV-1 gp140Î"V2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine, 2007, 25, 6882-6890.	3.8	11
175	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. Journal of Immunological Methods, 2012, 375, 46-56.	1.4	11
176	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.. EBioMedicine, 2021, 66, 103306.	6.1	11
177	Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. Vaccine, 2008, 26, 5182-5187.	3.8	10
178	Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice. Vaccine, 2009, 27, 4498-4507.	3.8	10
179	Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 939-946.	1.2	10
180	Pharmacological management of Kaposi's sarcoma. Expert Opinion on Pharmacotherapy, 2011, 12, 1669-1690.	1.8	10

#	Article	IF	Citations
181	Effect of MHC Haplotype on Immune Response upon Experimental SHIVSF162P4cy Infection of Mauritian Cynomolgus Macaques. PLoS ONE, 2014, 9, e93235.	2.5	10
182	Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy. Medicine (United States), 2016, 95, e5257.	1.0	10
183	CD8+CD28-T Lymphocytes from HIV-1-Infected Patients Secrete Factors That Induce Endothelial Cell Proliferation and Acquisition of Kaposi's Sarcoma Cell Features. Journal of Interferon and Cytokine Research, 2003, 23, 523-531.	1.2	9
184	Rational vaccine strategies against AIDS: background and rationale. Microbes and Infection, 2005, 7, 1445-1452.	1.9	9
185	Immune response and protection by DNA vaccines expressing antigen 85B ofMycobacterium tuberculosis. FEMS Microbiology Letters, 2006, 262, 210-215.	1.8	9
186	Characterization of HIV Type 1 Genetic Diversity Among South African Participants Enrolled in the AIDS Vaccine Integrated Project (AVIP) Study. AIDS Research and Human Retroviruses, 2010, 26, 705-709.	1.1	9
187	Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. Medical Science Monitor, 2006, 12, BR330-40.	1.1	9
188	Results in two infants with the DiGeorge syndromeâ€"Effects of long-term TP5. Clinical Immunology and Immunopathology, 1986, 39, 222-230.	2.0	8
189	Control of Human Herpes Virus Type 8-Associated Diseases by NK Cells. Annals of the New York Academy of Sciences, 2007, 1096, 37-43.	3.8	8
190	HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology. BMC Infectious Diseases, 2016, 16, 442.	2.9	8
191	Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells. Oncology Letters, 2017, 13, 2903-2908.	1.8	8
192	High HIV-1 diversity in immigrants resident in Italy (2008â€"2017). Scientific Reports, 2020, 10, 3226.	3.3	8
193	Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopeniaâ€Associated Aggressive Classic Kaposiâ€™s Sarcoma during Interferonâ€Ì± Therapy: A Case Report. Clinical Infectious Diseases, 2001, 33, 1782-1785.	5.8	7
194	Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIV_{SF162P4cy}. Tissue Antigens, 2012, 80, 36-45.	1.0	7
195	Efficacy ofantitatGene Therapy in the Presence of High Multiplicity Infection and Inflammatory Cytokines. Human Gene Therapy, 1996, 7, 2209-2216.	2.7	6
196	HHV-8 and multistep tumorigenesis. Trends in Microbiology, 1999, 7, 310-311.	7.7	6
197	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. Journal of Immunological Methods, 2004, 291, 153-163.	1.4	6
198	Non-neutralizing antibodies and vaccine-induced protection. Retrovirology, 2006, 3, S26.	2.0	6

#	Article	IF	Citations
199	Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. Seminars in Immunopathology, 2006, 28, 289-301.	4.0	6
200	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. Archives of Virology, 2021, 166, 2955-2974.	2.1	6
201	The use of HAART for biological tumour therapy. Journal of HIV Therapy, 2006, 11, 53-6.	0.6	6
202	Lytic Growth of Human Herpesvirus 8: Morphological Aspects. Ultrastructural Pathology, 2000, 24, 301-310.	0.9	5
203	HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction. Molecular Cancer Therapeutics, 2020, 19, 2476-2489.	4.1	5
204	Kaposi's sarcoma and AIDS. Nature, 1990, 346, 801-802.	27.8	4
205	Infection of a Simian B Cell Line by Human and Simian Immunodeficiency Viruses. AIDS Research and Human Retroviruses, 2004, 20, 723-732.	1.1	4
206	Primary Effusion Lymphoma Cells Undergoing Human Herpesvirus Type 8 Productive Infection Produce C-Type Retroviral Particles. International Journal of Immunopathology and Pharmacology, 2008, 21, 999-1006.	2.1	4
207	Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. Human Vaccines and Immunotherapeutics, 2015, 11, 1489-1493.	3.3	4
208	Old and New Concepts and Strategies in HIV Vaccinology: A Report from a Workshop held in Rome on 17 June 2016. Journal of AIDS & Clinical Research, 2016, 7, .	0.5	4
209	â€œcART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studiesâ€• Expert Review of Vaccines, 2017, 17, 1-12.	4.4	4
210	Biocompatible Anionic Polymeric Microspheres as Priming Delivery System for Effetive HIV/AIDS Tat-Based Vaccines. PLoS ONE, 2014, 9, e111360.	2.5	4
211	Tat protein vaccination of cynomolgus macaques influences SHIV-89.6Pcy243 epitope variability. Virus Genes, 2008, 36, 105-115.	1.6	3
212	Subtype Assignment and Phylogenetic Analysis of HIV Type 1 Strains in Patients from Swaziland. AIDS Research and Human Retroviruses, 2008, 24, 323-325.	1.1	3
213	Spindle cells from AIDS-associated Kaposi's sarcoma lesions express telomerase activity that is enhanced by Kaposi's sarcoma progression factors. Oncology Reports, 2010, 24, 219-23.	2.6	3
214	Molecular Characterization of HIV-1 Subtype C gp-120 Regions Potentially Involved in Virus Adaptive Mechanisms. PLoS ONE, 2014, 9, e95183.	2.5	3
215	The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation. Vaccines, 2020, 8, 274.	4.4	3
216	Kaposi's sarcomaâ€associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. Journal of Medical Virology, 2001, 65, 123-132.	5.0	3

#	Article	IF	Citations
217	Genetic diversity in the env V1-V2 region of proviral quasispecies from long-term controller MHC-typed cynomolgus macaques infected with SHIV SF162P4cy. Journal of General Virology, 2018, 99, 1717-1728.	2.9	3
218	Î³-Interferon Production in Peripheral Blood Mononuclear Cells and Tumor Infiltrating Lymphocytes From Kaposi's Sarcoma Patients: Correlation With the Presence of Human Herpesvirus-8 in Peripheral Blood Mononuclear Cells and Lesional Macrophages. Blood, 1998, 91, 968-976.	1.4	3
219	Induction of Antibodies and T Cell Responses by a Recombinant Influenza Virus Carrying an HIV-1 Tatî”51â€“59Protein in Mice. BioMed Research International, 2014, 2014, 1-10.	1.9	2
220	In Reply: Pseudotypes in HIV-Infected Mice. Science, 1990, 250, 1153-1154.	12.6	1
221	NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS*. Clinical Research and Regulatory Affairs, 2001, 18, 293-327.	2.1	1
222	Spindle cells from acquired immune deficiency syndromeâ€associated Kaposi's sarcoma lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factorâ€2. International Journal of Cancer, 2010, 127, 2487-2489.	5.1	1
223	HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine. Expert Review of Vaccines, 0, , 1-11.	4.4	1
224	Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity. JAMA - Journal of the American Medical Association, 1994, 272, 918.	7.4	0
225	P-451 HIV-protease inhibitors as antitumoral therapy in advanced NSCLC patients. Lung Cancer, 2005, 49, S235.	2.0	0
226	Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. Annals of Oncology, 2006, 17, 1335-1336.	1.2	0
227	190 IRF-1 is required for full NF-ÎºB transcriptional activity at the HIV-1 LTR enhancer. Cytokine, 2008, 43, 284.	3.2	0
228	ISOLATION OF HUMAN HERPESVIRUS-8 (HHV-8) FROM PBMC OF AIDS-KS PATIENTS AND VIRAL TRANSMISSION TO PRIMARY CELL CULTURE. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, A34.	0.3	0
229	Kaposiâ€™s Sarcoma Lesion Progression in BKV-Tat Transgenic Mice Is Increased by Inflammatory Cytokines and Blocked by Treatment with Anti-Tat Antibodies. International Journal of Molecular Sciences, 2022, 23, 2081.	4.1	0
230	Building up a collaborative network for the surveillance of HIV genetic diversity in Italy. A pilot study. Annali Dell'Istituto Superiore Di Sanita, 2015, 51, 321-6.	0.4	0